Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

Diabetes

TermDefinition
Glucagon Stimulate glycolysis; Stimulate hepatic gluconeogenesis and ketogenesis
Insulin Stimulate Glu uptake by muscles and adipose tissue; Suppress glucagon secretion; Stimulate glycogen, protein, and fat synthesis; Stimulate Glu use as energy
Amylin Suppress glucagon secretion; Slow gastric emptying; Reduce food intake and body weight
GLP-1 Stimulate Glu-dependent insulin release; Suppress glucagon secretion; Slow gastric emptying; Reduce food intake and body weight; Promote beta-cell health
ADA American Diabetes Association
AACE/ACE American Association of Clinical Endocrinologists/American College of Endocrinology
Diagnostic criteria for Pre-DM Fasting: 100-125 Postprandial: 140-199 A1C: 5.7-6.4% (ADA) or 5.5-6.4% (AACE)
ADA Targets Fasting: 80-130 Postprandial: <180 A1C: 7%
AACE/ACE Targets Fasting: <110 Postprandial: <140 A1C: <6.5%
DCCT T1DM: Aggressive Glu control (>3 shots/day or pump) decreases microvascular complications
UKPDS T2DM: Each 1% decrease in A1C = 35% reduction in microvascular complications; No impact on macrovascular; Metformin decreased macrovascular risk in obese populations
ACCORD T2DM: Ended early due to increased rate of mortality in intensive glycemic control group (A1C <6%)
ADVANCE T2DM: Intensive control (A1C <6.5%) decreased risk of renal events, but no difference in major macrovascular events
VADT T2DM: No difference in macrovascular events or mortality
Macrovascular Brain (stroke) Heart (CAD) Extremities (PVD)
Microvascular Eyes (retinopathy) Kidney (nephropathy) Nerves (neuropathy)
HTN Management Screening: annually Goal: <140/90 Treatment: lifestyle modifications and ACEI/ARB
Lipid Management Screening: at diagnosis and every 5 years Treatment: <40 and no risk factors = none; >40 and no risk factors = moderate; risk factors or ASCVD = high
High intensity statins Atorvastatin 40-80 mg Rosuvastatin 20-40 mg
Antiplatelet Therapy Primary Px: ASA if >50 + risk factor(s) Secondary Px: ASA 75-162 mg/day
Nephropathy Screening: annually Goal: urine albumin/Cr <30 Treatment: ACEI/ARB; protein restriction (0.8 g/kg/day)
Peripheral Neuropathy Screening: annual w/monofilament Treatment: TCAs, gabapentin, pregabalin, duloxetine, tapentadol
Retinopathy Screening: annual w/dilation Treatment: refer to ophthalmologist
Immunizations Annual flu vaccine Pneumococcal vaccine Hepatitis B vaccine
NICE-SUGAR Inpatient DM: Less stringent Glu control (<180) had decreased mortality and decreased hypogylcemia
Created by: kcapizzi